LATUDA is an atypical antipsychotic indicated for the treatment of patients with schizophrenia. Efficacy was established in five 6-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
In vitro receptor binding affinity
- Although the mechanism of action of LATUDA is unknown, the efficacy of LATUDA in schizophrenia could be mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism1
- The correlation between receptor-binding affinities and clinical outcomes is uncertain1
1. Latuda® (lurasidone HCl) prescribing information. Sunovion Pharmaceuticals Inc. July 2013.